Introduction
Quinolones have been employed to treat infections due to Neisseria gonorrhoeae, particularly for penicillin-resistant strains. 1 However, during recent years an increase in the number of clinical isolates of N. gonorrhoeae with a decreased susceptibility to these antibacterial agents has been reported. 1, 2 Moreover, development of resistance during treatment with fluoroquinolones and therapeutic failure have been described. 1, 2 In vitro studies to establish the potential of different quinolones to select resistant mutants have been conducted on various microorganisms. [3] [4] [5] [6] In a series of 10 Gramnegative and Gram-positive microorganisms, not including N. gonorrhoeae, it has been shown 5 that gemifloxacin has a low level of selection of resistant mutants, which is even lower than that of ciprofloxacin or trovafloxacin. Gemifloxacin is a novel fluoroquinolone that possesses enhanced activity against both Gram-negative and Gram-positive microorganisms.
7 Previous studies have shown that it has excellent activity against N. gonorrhoeae. 7, 8 However, the role of this quinolone in the selection of resistant mutants of N. gonorrhoeae remains unknown.
The ability of antibacterial agents to select resistant mutants is a critical factor in their therapeutic usefulness. An antibacterial agent with high in vitro capacity to select resistant mutants may, potentially, act in a similar way during treatment, especially if the treatment is prolonged and subinhibitory concentrations are achieved in the infected tissue.
9 Thus, evaluating the role of a new antibacterial agent in the development of resistant strains compared with other antibacterial agents may indicate the potential risk of developing resistance during therapy.
The aim of this study was to determine the frequency at which fluoroquinolone-resistant mutants were selected from two nalidixic acid susceptible and two nalidixic acidresistant strains of N. gonorrhoeae exposed to gemifloxacin and four other fluoroquinolones.
Materials and methods

Microorganisms
Four clinical isolates of N. gonorrhoeae analysed previously were used for the study. 8 Two were resistant to nalidixic acid by virtue of a single mutation in codon 91 of the gyrA gene (SerǞLeu and SerǞPhe, respectively), whereas the other two were susceptible to nalidixic acid with no detectable alteration in either the gyrA or parC gene. 
Antimicrobial susceptibility testing
Determination of spontaneous single-step resistance rates
The determination of spontaneous single-step resistance rates was performed as described previously, 4 with the modification that the isolates were grown on GC-agar and then resuspended in saline solution before inoculation on to GC-agar containing the selected antibacterial agent at 2 ϫ, 4 ϫ and 8 ϫ MIC. The plates were read at 24 and 48 h. The frequency of spontaneous resistance selected by each fluoroquinolone was calculated as the ratio of the number of bacteria growing divided by the number of bacteria in the original inoculum. The strains that did not appear on the plates were given a frequency of resistance reciprocal to that of the inoculum. The experiments were repeated three times.
Stability of the resistance
To establish the resistance stability of mutants, a representative mutant colony from each concentration of antibacterial agent was subcultured onto plates without antibacterial agent prior to MIC determination.
Analysis of the mutations present in the gyrA and parC genes
A fragment of the gyrA and parC genes containing the so-called 'quinolone resistance-determining region' was amplified using previously described primers and conditions.
2,8
Results and discussion
The susceptibility and genetic characteristics of the wildtype quinolone-susceptible strains and strains having a previous mutation in the gyrA gene used in this study are shown in Table 1 . Mutants able to grow at 2 ϫ, 4 ϫ or 8 ϫ MIC were obtained with all quinolones tested, except gemifloxacin (Table 2 ). This finding is similar to those previously reported, 5 which indicated that gemifloxacin selected resistant mutants at a lower frequency in Gram-negative and Gram-positive microorganisms, not including N. gonorrhoeae, compared with ciprofloxacin and trovafloxacin. In order to establish the frequency of mutation, all the colonies that grew on antibiotic-containing agar were considered as mutants, regardless of their MIC stability. The frequency of mutation with the quinolones analysed was low. Only when strain 97-692 was grown on agar containing trovafloxacin at 2 ϫ MIC, and when strain 3174 was grown on ciprofloxacin at 2 ϫ and 4 ϫ MIC was the frequency of mutation in the order of 10 Ϫ7 . No differences were found when the plates were read at 24 and 48 h.
Only one strain (3174) selected at 4 ϫ MIC of trovafloxacin presented a stable increase in its MIC from 0.06 to 0.25 mg/L of this antibacterial agent alone, i.e. did not present alterations in the MICs of the other quinolones studied. This phenomenon indicates that strain 3174 presents a particular system able to increase the MIC of trovafloxacin, but which does not affect gemifloxacin or the other quinolones studied. When the presence of alterations in the quinolone targets of this mutant was studied no new mutations were found in either the gyrA or parC gene, other than the previously described mutations in the parental strain. The other mutants selected did not present stable increases in the MICs of tested quinolones. The fact that strains able to grow in a medium with a concentration of an antibacterial agent above its MIC do not present a stable increase in the MIC of this antibacterial agent may be due to a temporary induction of some mechanism(s) of quinolone resistance, such as overexpression of some efflux pumps, in the presence of the fluoroquinolone, which reverts when the strain is grown in the absence of the antibiotic. If this were the case, the accumulation of fluoroquinolone would be lower but would favour the development of higher resistance.
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In two different models (Gram-positive and Gramnegative) Drugeon et al. 3 and Tavio et al. 6 reported a higher frequency of mutation presented by strains carrying mutations in their quinolone targets. This phenomenon was not seen in our strains, which may be attributable to the high activity of the quinolones against N. gonorrhoeae. 1, 7, 8 Despite this low frequency of mutation, the increase in resistance levels to quinolones among clinical isolates of N. gonorrhoeae is continuously rising.
The low level of selection by gemifloxacin of quinolone resistance in N. gonorrhoeae, together with its good activity against clinical isolates already carrying a substitution in GyrA, 8 indicates that this quinolone may have an important role to play in the treatment of gonococcal infections. 
